abstract: Stanford university researchers found in mice, low doses of nicotine (the main ingredient) have cigarette promote angiogenesis or promote the growth of new blood vessels role.
Washington, September 13 (Reuters medical news) Stanford university researchers found in mice, low doses of nicotine (the main ingredient) have cigarette promote angiogenesis or promote the growth of new blood vessels role.
although Stanford university researchers say these findings may help explain how smoking causing cancer, but biotechnology company Endovasc plan to use the results to treat heart disease.
Endovasc company President and general manager dr David Summers told Reuters in a meeting with Endovasc company, already from Stanford university won the nicotine promote angiogenesis, and the right role in are developing a kind of liposome based transmission system, make physician will give a drug from the vein occlusion of the blood vessel heart attacks or the patient.
Summers explained that this kind of liposomes vesicles stays in the area of injury, release drug lasted more than three to four weeks. He doesn't hope drug longer, because nicotine is promoting angiogenesis role, so there is always stimulate cancerous risk.
Summers remarked: "& ldquo; For heart patients, speaking, if can in the heart of the lower limbs and other parts around to promote angiogenesis, we can cancel surgery and remove with the risk of surgery. & rdquo;
he says his company in animal studies, plan had success in Europe before the end of start clinical trials.
Stanford university agreed to use Endovasc company has all kinds of ways, including the sole agency for oral, tablet or injection. Endovasc said, this means that anyone will be used to promote angiogenesis nicotine might be Endovasc company to pay taxes. The company is working with Abbott and some other large pharmaceutical companies about access to discuss matters of nicotine permission.
held in Amsterdam in the 22nd European heart association annual meeting of Stanford university published research published in the European heart journal on September 8/John. John p. dr Cooke and colleagues at Stanford university medical school in California to implement the tests. In mice
